TrialCancer chemotherapy and pharmacology2023

An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose.

Bart A Jessen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.